All Outputs (25)

Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis (2022)
Journal Article
Gordon, M., Sinopoulou, V., Akobeng, A. K., Pana, M., Gasiea, R., & Moran, G. W. (2022). Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. Cochrane Library, 2022(4), 1-55. https://doi.org/10.1002/14651858.CD007216.pub2

Background: There are a limited number of treatment options for people with corticosteroid-refractory ulcerative colitis. Animal models of inflammatory bowel disease and uncontrolled studies in humans suggest that tacrolimus may be an effective treat... Read More about Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis.

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab (2022)
Journal Article
Lin, S., Kennedy, N. A., Saifuddin, A., Sandoval, D. M., Reynolds, C. J., Castro Seoane, R., …Jones, G. (2022). Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 13, Article 1379. https://doi.org/10.1038/s41467-022-28517-z

Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal and influenza vaccination. Here we report SARS-CoV-2 vaccine-induced immune responses and breakthrou... Read More about Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.

Current Use of EEN in Pre-Operative Optimisation in Crohn’s Disease (2021)
Journal Article
Shariff, S., Moran, G., Grimes, C., & Cooney, R. M. (2021). Current Use of EEN in Pre-Operative Optimisation in Crohn’s Disease. Nutrients, 13(12), Article 4389. https://doi.org/10.3390/nu13124389

Despite the increasing array of medications available for the treatment of Crohn’s disease and a focus on mucosal healing, approximately 35% of patients with Crohn’s disease undergo bowel surgery at some stage. The importance of nutritional optimisat... Read More about Current Use of EEN in Pre-Operative Optimisation in Crohn’s Disease.

Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic (2021)
Journal Article
Din, S., Gaya, D., Kammermeier, J., Lamb, C. A., Macdonald, J., Moran, G., …Arnott, I. D. (2022). Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterology, 13(1), 77-81. https://doi.org/10.1136/flgastro-2021-101805

Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study (2021)
Journal Article
Sebastian, S., Walker, G. J., Kennedy, N. A., Conley, T. E., Patel, K. V., Subramanian, S., …Zafar, M. (2021). Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. Lancet Gastroenterology and Hepatology, 6(4), 271-281. https://doi.org/10.1016/s2468-1253%2821%2900016-9

Background
There is a paucity of evidence to support safe and effective management of patients with acute severe ulcerative colitis during the COVID-19 pandemic. We sought to identify alterations to established conventional evidence-based management... Read More about Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.